Maharashtra: Government-Run Blood Banks Slapped Rs 12.72 Lakh In Fines For Neglecting Daily Stock Updates, Reveals RTI Inquiry

Mumbai: The State Blood Transfusion Council imposed a fine of over Rs 12,72,000 on 93 government-run blood banks between December 2022 to April 2023 for not updating the daily blood stock at MahaSBTC and e-raktkosh portal.

The data was revealed through a Right To Information (RTI) filed by activist Chetan Kothari seeking data regarding penalties imposed on blood banks in the last five months. As per the RTI, RN Cooper blood banks tops the list of penalties in terms of violation. Out of a total 121 days, the blood bank has uploaded its blood stock on e-raktkosh only for 25 days.

“The daily stock on e-raktkosh has not been updated 11 times in December 2022, followed by 22 times in January 2023, six times in February, 27 times in March and 30 days in April. All these clearly show that blood banks have not taken GR seriously,” said Kothari.

The public health department had released a government resolution (GR) on December 2 stating that if banks are charging processing fee in excess of the amount stipulated by the National Blood Transfusion Council (NBTC), a penalty of five times the extra processing fee will be levied on the bank.

A senior blood transfusion officer said that often the families of the patients are least aware of the availability of the blood at blood banks. In view of this, the government created the e-blood bank website on which blood banks of all the states have to upload information about their stock. “The basic objective is that whenever a patient needs blood and there is no blood in the blood bank of the hospital, then they can go to thee-blood bank and search in which blood bank the blood is available,” he said.

 

Related Posts

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care